Literature DB >> 8701589

Optimization of the intestinal lavage procedure for determination of intestinal immune responses.

C Ahrén1, K Andersson, G Wiklund, C Wennerås, A M Svennerholm.   

Abstract

Optimal conditions to process, concentrate and store intestinal lavage fluid were studied in samples collected from volunteers before and after oral immunization with a prototype vaccine against enterotoxigenic Escherichia coli (ETEC) diarrhoea. Total IgA and specific IgA antibody titres against enterotoxin and colonization factor antigen were determined in 22 lavage samples which were either enzyme-inhibited or heat-inactivated and then subjected to different long-term storage conditions. Samples were analysed within 1 month of collection and also after 3, 6 and 24 months of storage. Total IgA concentrations and specific IgA antibody levels were higher in lavage samples treated with enzyme inhibitors (soybean trypsin inhibitor and phenylmethylsulfonyl fluoride) than in those heat-inactivated. Similarily, concentration of the lavage fluid by freeze-drying was superior to concentration against polyethylene glycol. Specific antibody titres remained elevated after storage for at least 6 months but declined after 2 years in frozen compared with freeze-dried samples.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8701589     DOI: 10.1016/0264-410x(95)00153-r

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Correlations between antibody immune responses at different mucosal effector sites are controlled by antigen type and dosage.

Authors:  D Externest; B Meckelein; M A Schmidt; A Frey
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  Immune responses in ileostomy fluid and serum after oral cholera vaccination of patients colectomized because of ulcerative colitis.

Authors:  J Kilhamn; H Brevinge; A M Svennerholm; M Jertborn
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

Review 3.  Rectal effluent as a research tool.

Authors:  Jana M Rocker; Jack A DiPalma; Lewis K Pannell
Journal:  Dig Dis Sci       Date:  2014-09-02       Impact factor: 3.199

4.  Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood.

Authors:  C Ahrén; M Jertborn; A M Svennerholm
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

5.  Systemic and mucosal immune responses following oral adenoviral delivery of influenza vaccine to the human intestine by radio controlled capsule.

Authors:  Leesun Kim; C Josefina Martinez; Katie A Hodgson; George R Trager; Jennifer R Brandl; Erik P Sandefer; Walter J Doll; Dave Liebowitz; Sean N Tucker
Journal:  Sci Rep       Date:  2016-11-24       Impact factor: 4.379

6.  Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.

Authors:  Marjahan Akhtar; Mohiul I Chowdhury; Taufiqur R Bhuiyan; Joanna Kaim; Tasnuva Ahmed; Tanzeem A Rafique; Arifuzzaman Khan; Sadia I A Rahman; Farhana Khanam; Yasmin A Begum; Mir Z Sharif; Laila N Islam; Nils Carlin; Nicole Maier; Alan Fix; Thomas F Wierzba; Richard I Walker; A Louis Bourgeois; Ann-Mari Svennerholm; Firdausi Qadri; Anna Lundgren
Journal:  Vaccine       Date:  2018-11-22       Impact factor: 3.641

7.  Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.

Authors:  Firdausi Qadri; Marjahan Akhtar; Taufiqur R Bhuiyan; Mohiul I Chowdhury; Tasnuva Ahmed; Tanzeem A Rafique; Arifuzzaman Khan; Sadia I A Rahman; Farhana Khanam; Anna Lundgren; Gudrun Wiklund; Joanna Kaim; Madeleine Löfstrand; Nils Carlin; A Louis Bourgeois; Nicole Maier; Alan Fix; Thomas Wierzba; Richard I Walker; Ann-Mari Svennerholm
Journal:  Lancet Infect Dis       Date:  2019-11-19       Impact factor: 25.071

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.